Cellectis S A : PRELIMINARY NOTE - Form 6-K : vimarsana.com

PRELIMINARY NOTE


The unaudited condensed Consolidated Financial Statements for the three-month period ended March 31, 2023, included herein, have been prepared in... | May 4, 2023

Related Keywords

Boston , Massachusetts , United States , New Jersey , Paris , France General , France , China , Pennsylvania , Florida , Minnesota , Texas , Philadelphia , Spain , University Of Texas , Chicago , Illinois , California , New York , French , American , Iovance Biotherapeutics , Lyon , Pontchaillou Rennes , Monte Carlo , Navarra Pamplona , Robert Debr , Los Angeles , Trustee Of University Pennsylvania Philadelphia , Brigham Cancer Care Inc , Exchange Commission , Euronext , University Of Minnesota , Calypso Merger Subsidiary , Austin Medical Center , Program On Nasdaq , Calyxt Inc , Paris Administrative Court , International Accounting Standards Board , Clinical Research , Group Share , Research Tax Credit , University Of Chicago , International Accounting Standards , Management Services Agreement , Cytovia Therapeutics Inc , Sarah Cannon Research Institute , Cibus Global , Northwestern University Chicago , Compensation Committee Of Calyxt Board , Regents Of The University California , International Accounting Standard , American Association For Cancer Research , Cellectis Biologics Inc , University Piscatawaya , Purpose Acquisition Company , Additional Ordinary Shares Of The Company , Group Consolidated Operations , French Tax Authority , Cellectis Inc , Standards Interpretation Committee , Md Anderson Cancer Center Houston , American Society Of Clinical Oncology , Memorial Sloan Kettering Cancer Center New York , Barclays Capital Inc , European Investment Bank , International Financial Reporting Standards , International Financial Reporting Interpretations Committee , Dana Farber Partners Cancercare Inc , Regent Of The University California , Consolidated Financial Statements , Financial Reporting , Financial Condition , Private Securities Litigation Reform Act , Note Regarding Forward Looking , Annual Report , Plant Cell , Cellectis Biologics , Consolidated Interim Financial , American Depositary Shares , Cellectis Follow On Offering , Chimeric Antigen Receptort Cells , Chimeric Antigen Receptors , Interim Consolidated Financial Statements , Initial Application , Accounting Estimates , Accounting Policies , Deferred Tax , Single Transaction , With Calyxt , Calyxt Merger , Nasdaq Capital Market , Bid Price Rule , Reverse Stock Split , Reverse Stock , Chief Operating Decision Maker , Chief Executive Officer , Executive Vice President Strategic Initiatives , Senior Vice President , Chief Scientific Officer , General Counsel , Chief Business Officer , Chief Regulatory , Pharmaceutical Compliance Officer , Chief Medical Officer , Management Services , Assets Held , Discontinued Operations , Merger Agreement , Cytovia Therapeutics , Pluripotent Stem Cell , Natural Killer , Cytovia Agreement , Cytolynkx Therapeutics , Cytovia Conditions , Special Purpose Acquisition Company , Upfront Collaboration , Banque Palatine , French Government , State Guaranteed , Inducement Plan , Compensation Committee , Finance Contract , French Commercial Code , Restated Certificate , Commercialization Agreement , License Agreement , Allogene License Agreement , Servier License Agreement , Allogene License , Cancer Center , Moffitt Cancer Center , Research Institute , Partners Cancercare , New York Presbyterian , Weill Medical College , Cornell University , Northwestern University , San Francisco Campus , San Francisco , Roswell Park Cancer Institute Corporation , Roswell Park Comprehensive Cancer Center , Memorial Sloan Kettering Cancer Center , Mass General Brigham Cancer Care , Hospices Civils De Lyon , Dose Level , Clinica Universidad De Navarra , State University , American Society , Clinical Oncology , Annual Meeting June , American Association , Cancer Research , Annual Meeting , Combined General Meeting , Barclays Capital , Stock Split , North Carolina , Net Income , Adjusted Net Income , Euronext Growth , Nasdaq Global Market , Interim Funding , Cellecti Therapeutic , Qualitative Disclosures About Market , Qualitative Disclosures About Market Risk , Sarbanes Oxley Act , Cellecti Annual Report , Equity Securities , Cellectis Sa Stock Exchange , News , Information , Press Release , Reliminary , The , Naudited , Ondensed , Onsolidated , Financial , Statements , Or , Eriod , Nded , Arch , Ncluded , Wave , Teen , Repared Alcls Fr0010425595 ,